Compare LEGH & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LEGH | CTNM |
|---|---|---|
| Founded | 2005 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 620.7M | 550.7M |
| IPO Year | 2018 | 2024 |
| Metric | LEGH | CTNM |
|---|---|---|
| Price | $27.68 | $16.07 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $25.00 | $19.00 |
| AVG Volume (30 Days) | 73.1K | ★ 534.7K |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.46 |
| EPS | ★ 1.44 | N/A |
| Revenue | ★ $164,567,000.00 | N/A |
| Revenue This Year | $11.90 | N/A |
| Revenue Next Year | $6.58 | N/A |
| P/E Ratio | $19.73 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $18.29 | $8.60 |
| 52 Week High | $31.34 | $17.79 |
| Indicator | LEGH | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 46.11 | 51.38 |
| Support Level | $25.03 | $13.65 |
| Resistance Level | $30.92 | $16.86 |
| Average True Range (ATR) | 0.85 | 0.94 |
| MACD | -0.18 | -0.05 |
| Stochastic Oscillator | 8.28 | 49.92 |
Legacy Housing Corp builds, sells, and finances manufactured homes and tiny houses that are distributed through a network of independent retailers and company-owned stores, and are also sold directly to manufactured home communities. The Company manufactures and provides for the transport of manufactured homes, provides wholesale financing to dealers and mobile home parks, provides retail financing to consumers, and is involved in financing and developing new manufactured home communities. The Company manufactures its mobile homes at plants in Fort Worth, Texas; Commerce, Texas; and Eatonton, Georgia. The Company also sells homes directly to consumers, through its own retail stores, and to dealers and mobile home parks.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.